Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_assertion type Assertion NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_head.
- NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_assertion description "[Almost all activated B cell-like (ABC) DLBCL, which is the least curable group among the 3 major subtypes of this malignancy, and a substantial fraction of germinal center B cell-like (GCB) DLBCL exhibit constitutive NF-?B pathway activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_provenance.
- NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_assertion evidence source_evidence_literature NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_provenance.
- NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_assertion SIO_000772 22791293 NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_provenance.
- NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_assertion wasDerivedFrom befree-20140225 NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_provenance.
- NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_assertion wasGeneratedBy ECO_0000203 NP608057.RAtVykR-V_Euqurvrx_uf2aBeFBvunzKfLM905tlo-jGs130_provenance.